Literature DB >> 25989033

[Clinical Signs of Ocular Graft-versus-Host Disease].

T Dietrich-Ntoukas1.   

Abstract

BACKGROUND: Ocular graft-versus-host disease (GvHD) is mainly an inflammatory ocular surface disorder after allogeneic hematopoetic stem cell transplantation (HSCT) with increasing incidence.
METHODS: We present an overview on clinical signs of ocular GvHD.
RESULTS: Ocular chronic GvHD representing a severe ocular surface disease is a long-term problem after allogeneic HSCT. It is not only associated with reduced quality of life because of dry eye symptoms but can also impair visual acuity and lead to blindness due to corneal complications. Patients with ocular GvHD are often resistant to therapy because of the severe dry eye disease and persistent inflammatory activity.
CONCLUSION: A multimodal and interdisciplinary therapy - in cooperation with the colleagues from haematology and oncology is important for the treatment of patients with ocular GvHD. Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Year:  2015        PMID: 25989033     DOI: 10.1055/s-0035-1545836

Source DB:  PubMed          Journal:  Klin Monbl Augenheilkd        ISSN: 0023-2165            Impact factor:   0.700


  2 in total

1.  Two case reports of continued progression of chronic ocular graft-versus-host disease without concurrent systemic comorbidities treated by amniotic membrane transplantation.

Authors:  Hideto Ikarashi; Naohiko Aketa; Eisuke Shimizu; Yoji Takano; Tetsuya Kawakita; Yuichi Uchino; Yukihiro Matsumoto; Junko Ogawa; Kazuo Tsubota; Yoko Ogawa
Journal:  BMC Ophthalmol       Date:  2021-04-07       Impact factor: 2.209

2.  Detection of systemic immunosuppressants in autologous serum eye drops (ASED) in patients with severe chronic ocular graft versus host disease.

Authors:  Volkan Tahmaz; Martin H J Wiesen; Uta Gehlsen; Laura Sauerbier; Michael E Stern; Udo Holtick; Birgit Gathof; Christof Scheid; Carsten Müller; Philipp Steven
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2020-08-19       Impact factor: 3.117

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.